Converse Cuts Corporate Jobs as Nike Restructures to Revive Sales Growth 
Ancora Holdings Builds $200M Stake in Warner Bros Discovery, Targets Netflix Asset Sale Plan 
Russia Moves to Fully Block WhatsApp as Kremlin Pushes State-Backed MAX App 
Russia Signals Further Restrictions on Telegram Amid Ongoing Regulatory Disputes 
Gates Foundation Denies Financial Ties to Jeffrey Epstein Following DOJ Email Release 
Ralph Lauren Unveils Elegant Fall 2026 Women’s Collection Ahead of New York Fashion Week 
FTC Questions Apple News Over Alleged Bias Against Conservative Media 
Instagram CEO Defends Platform in Youth Mental Health Lawsuit Over Social Media Addiction Claims 
Michael Kors Marks 45 Years at New York Fashion Week with Fall/Winter Collection Showcase 
Xiaomi EV Deliveries Surpass 600,000 Units as SU7 and YU7 Drive Strong Growth 
Air New Zealand Cabin Crew Strike Set for February 12–13 Amid Failed Talks 
Westpac (ASX: WBC) Q1 Profit Rises 6% as Lending Growth and Treasury Income Strengthen Earnings 
FDA Rejects Review of Moderna’s Flu Vaccine Application, Shares Slide 
AbbVie Sues HHS Over Medicare Price Controls on Botox Under Inflation Reduction Act 
How Marco Pharma International Preserves German Homeopathic Traditions in America 
More U.S. Investors Join Arbitration Against South Korea Over Coupang Dispute 
GE Aerospace Expands Singapore Engine Repair Hub with Automation and AI to Tackle Aviation Bottlenecks 
DURHAM, N.C., Nov. 07, 2017 -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company developing novel antivirals to address unmet medical needs, today announced that M. Michelle Berrey, M.D., M.P.H., Chief Executive Officer of Chimerix and Garrett Nichols, M.D., M.S., Chief Medical Officer of Chimerix will participate in a fireside chat at the Stifel 2017 Healthcare Conference on Tuesday, November 14, 2017 at 11:45 a.m. ET at the Lotte New York Palace Hotel in New York City.
A live audio webcast of the presentation will be available on the Investor Relations section of Chimerix’s website at ir.chimerix.com, where it will be archived for approximately 90 days.
About Chimerix
Chimerix is a biopharmaceutical company dedicated to discovering, developing and commercializing medicines that improve outcomes for immunocompromised patients. Chimerix's proprietary lipid conjugate technology and compound library have produced brincidofovir (BCV, CMX001); CMX157, which was licensed to ContraVir Pharmaceuticals; and a new clinical candidate, CMX521, for the treatment and prevention of norovirus. For further information, please visit Chimerix's website, www.chimerix.com.
CONTACT:
Investor Relations:
[email protected]
or
Will O’Connor
Stern Investor Relations
[email protected]
212-362-1200
Media:
Becky Vonsiatsky
W2O Group
[email protected]
413-478-2003
